Adjuvant Chemotherapy for Endometrial cancer Trial: A randomised phase II study of TEC, TAC and ddTC for endometrial carcinoma
Phase 2
- Conditions
- Endometrial carcinoma with risk factors of recurrence.
- Registration Number
- JPRN-UMIN000008368
- Lead Sponsor
- Gynecologic Oncology Group of Osaka (GOGO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with sarcomatous element 2)Active infections 3)Serious complications (heart disease, uncontrolled diabetes mellitus, malignant hypertension and tendency to bleeding) 4)Active concomitant malignancy 5)Interstitial pneumonitis and plumonary fibrosis 6)Massive pleural effusion or ascites 7)Neuropathy grade 2 or more (NCI-CTC) 8)Edema grade 2 or more (NCI-CTC) 9)prior chemotherapy including doxorubicin 10)Hypersensitivity to Polysorbate 80 or Cremophor EL 11)patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant 12)Patients judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS, completion rate of chemotherapy
- Secondary Outcome Measures
Name Time Method OS, side effects, response rate